Hemostemix Inc. (CVE:HEM – Get Free Report) shares traded up 27.9% on Thursday . The stock traded as high as C$0.29 and last traded at C$0.28. 1,401,717 shares traded hands during mid-day trading, an increase of 100% from the average session volume of 700,303 shares. The stock had previously closed at C$0.22.
Hemostemix Stock Up 27.9 %
The firm has a market cap of C$23.96 million, a PE ratio of -13.75 and a beta of 0.20. The company’s 50 day moving average price is C$0.10 and its two-hundred day moving average price is C$0.08.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Articles
- Five stocks we like better than Hemostemix
- What is the S&P 500 and How It is Distinct from Other Indexes
- Cerence AI: One-Hit Wonder or Long-Term Winner After NVIDIA Pact?
- 3 Best Fintech Stocks for a Portfolio Boost
- UnitedHealth Group Pulls Back Into Another Healthy Opportunity
- What is a SEC Filing?
- Micron Technology: Riding the AI Wave to Long-Term Growth
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
